PREDICTIVE ONCOLOGY INC (POAI) Fundamental Analysis & Valuation

NASDAQ:POAI • US74039M4087

Current stock price

5.95 USD
+0.03 (+0.51%)
At close:
5.8945 USD
-0.06 (-0.93%)
After Hours:

This POAI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. POAI Profitability Analysis

1.1 Basic Checks

  • In the past year POAI has reported negative net income.
  • POAI had a negative operating cash flow in the past year.
  • POAI had negative earnings in each of the past 5 years.
  • POAI had a negative operating cash flow in each of the past 5 years.
POAI Yearly Net Income VS EBIT VS OCF VS FCFPOAI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

  • The Return On Assets of POAI (-2688.13%) is worse than 98.40% of its industry peers.
Industry RankSector Rank
ROA -2688.13%
ROE N/A
ROIC N/A
ROA(3y)-150.57%
ROA(5y)-139.82%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
POAI Yearly ROA, ROE, ROICPOAI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5K -5K -10K -15K -20K

1.3 Margins

  • With a Gross Margin value of 50.26%, POAI perfoms like the industry average, outperforming 44.92% of the companies in the same industry.
  • POAI's Gross Margin has declined in the last couple of years.
  • POAI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 50.26%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.14%
GM growth 5Y-4.67%
POAI Yearly Profit, Operating, Gross MarginsPOAI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. POAI Health Analysis

2.1 Basic Checks

  • POAI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • POAI has more shares outstanding than it did 1 year ago.
  • POAI has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for POAI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
POAI Yearly Shares OutstandingPOAI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100K 200K 300K 400K
POAI Yearly Total Debt VS Total AssetsPOAI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

  • POAI has an Altman-Z score of -157.16. This is a bad value and indicates that POAI is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -157.16, POAI is not doing good in the industry: 96.26% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -157.16
ROIC/WACCN/A
WACC8.8%
POAI Yearly LT Debt VS Equity VS FCFPOAI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M 40M

2.3 Liquidity

  • POAI has a Current Ratio of 0.01. This is a bad value and indicates that POAI is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 0.01, POAI is doing worse than 99.47% of the companies in the same industry.
  • A Quick Ratio of 0.01 indicates that POAI may have some problems paying its short term obligations.
  • With a Quick ratio value of 0.01, POAI is not doing good in the industry: 99.47% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.01
Quick Ratio 0.01
POAI Yearly Current Assets VS Current LiabilitesPOAI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. POAI Growth Analysis

3.1 Past

  • POAI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -163.00%.
  • The Revenue for POAI has decreased by -47.20% in the past year. This is quite bad
  • Measured over the past years, POAI shows a small growth in Revenue. The Revenue has been growing by 2.86% on average per year.
EPS 1Y (TTM)-163%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1379.27%
Revenue 1Y (TTM)-47.2%
Revenue growth 3Y4.57%
Revenue growth 5Y2.86%
Sales Q2Q%-98.96%

3.2 Future

  • Based on estimates for the next years, POAI will show a very strong growth in Earnings Per Share. The EPS will grow by 26.17% on average per year.
  • Based on estimates for the next years, POAI will show a very strong growth in Revenue. The Revenue will grow by 158.10% on average per year.
EPS Next Y99.58%
EPS Next 2Y41.51%
EPS Next 3Y26.17%
EPS Next 5YN/A
Revenue Next Year569.48%
Revenue Next 2Y232.87%
Revenue Next 3Y158.1%
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
POAI Yearly Revenue VS EstimatesPOAI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M 800M 1B
POAI Yearly EPS VS EstimatesPOAI Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 0 -100 -200 -300 -400

More info and screens

Find the best growth stocksShow best growing peers

2

4. POAI Valuation Analysis

4.1 Price/Earnings Ratio

  • POAI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • With a Price/Forward Earnings ratio of 72.92, POAI can be considered very expensive at the moment.
  • POAI's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. POAI is cheaper than 66.31% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 22.19, POAI is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 72.92
POAI Price Earnings VS Forward Price EarningsPOAI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
POAI Per share dataPOAI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60 -80 -100

4.3 Compensation for Growth

  • POAI's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • POAI's earnings are expected to grow with 26.17% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.51%
EPS Next 3Y26.17%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. POAI Dividend Analysis

5.1 Amount

  • POAI does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

POAI Fundamentals: All Metrics, Ratios and Statistics

PREDICTIVE ONCOLOGY INC

NASDAQ:POAI (12/11/2025, 8:01:54 PM)

After market: 5.8945 -0.06 (-0.93%)

5.95

+0.03 (+0.51%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-14
Earnings (Next)03-30
Inst Owners0.15%
Inst Owner Change561.87%
Ins Owners3.21%
Ins Owner Change-0.08%
Market Cap88.66M
Revenue(TTM)728.20K
Net Income(TTM)-84.33M
Analysts43.33
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-99.79%
Min Revenue beat(2)-99.82%
Max Revenue beat(2)-99.76%
Revenue beat(4)1
Avg Revenue beat(4)-55.24%
Min Revenue beat(4)-99.82%
Max Revenue beat(4)71.43%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 72.92
P/S 121.75
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-120.64
EYN/A
EPS(NY)0.08
Fwd EY1.37%
FCF(TTM)-0.53
FCFYN/A
OCF(TTM)-0.53
OCFYN/A
SpS0.05
BVpS-5.2
TBVpS-5.2
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -2688.13%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 50.26%
FCFM N/A
ROA(3y)-150.57%
ROA(5y)-139.82%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.14%
GM growth 5Y-4.67%
F-Score4
Asset Turnover0.23
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.01
Quick Ratio 0.01
Altman-Z -157.16
F-Score4
WACC8.8%
ROIC/WACCN/A
Cap/Depr(3y)20.65%
Cap/Depr(5y)33.78%
Cap/Sales(3y)11.77%
Cap/Sales(5y)26.34%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-163%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1379.27%
EPS Next Y99.58%
EPS Next 2Y41.51%
EPS Next 3Y26.17%
EPS Next 5YN/A
Revenue 1Y (TTM)-47.2%
Revenue growth 3Y4.57%
Revenue growth 5Y2.86%
Sales Q2Q%-98.96%
Revenue Next Year569.48%
Revenue Next 2Y232.87%
Revenue Next 3Y158.1%
Revenue Next 5YN/A
EBIT growth 1Y21.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y42.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y40.91%
OCF growth 3YN/A
OCF growth 5YN/A

PREDICTIVE ONCOLOGY INC / POAI Fundamental Analysis FAQ

What is the ChartMill fundamental rating of PREDICTIVE ONCOLOGY INC (POAI) stock?

ChartMill assigns a fundamental rating of 1 / 10 to POAI.


What is the valuation status for POAI stock?

ChartMill assigns a valuation rating of 2 / 10 to PREDICTIVE ONCOLOGY INC (POAI). This can be considered as Overvalued.


What is the profitability of POAI stock?

PREDICTIVE ONCOLOGY INC (POAI) has a profitability rating of 0 / 10.